This vaccine is designed for individuals aged six months and older and is expected to enhance immunity against current and emerging SARS-CoV-2 lineages. The authorization follows a recommendation from the European Medicines Agency’s Emergency Task Force, which indicated that the XFG-targeted formulation would provide optimal protection. Pfizer and BioNTech have commenced manufacturing to ensure timely distribution across the EU and associated countries, with over five billion doses of their vaccines already administered globally.